AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25240629
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid eye drops (0.5% loteprednol etabonate) 4 times daily for 15 days
Trial: 22829151
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment as usual, N = 13)
Trial: 17464237
Drug: Isoflavone (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone (75 mg of isoflavone conjugates/day)
Trial: 10229408
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release oxycodone
Trial: 9646650
Drug: Nasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal ketamine 0.25 mg/kg
Trial: 9646650
Drug: Nasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal ketamine 5 mg/kg
Trial: 8709686
Drug: AZT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT plus ddl (400 mg per day)
Trial: 8709686
Drug: AZT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT plus ddC (2.25 mg per day)
Trial: 8709686
Drug: AZT (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT (600 mg per day) alone
Trial: 2321571
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1500 mg total, three times daily with meals for 5.5 weeks)
Trial: 25471276
Drug: Additional androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional androgen deprivation therapy (ADT)
Trial: 19587642
Drug: CP‐800,569 (30‐1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐800,569 (30‐1,800 mg once daily for 14 days)
Trial: 19587642
Drug: CP‐800,569 (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐800,569 (1,800 mg)
Trial: 19587642
Drug: CP‐800,569 (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐800,569 (higher doses)
Trial: 1467292
Drug: Acitretin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (50 mg/day)
Trial: 26525882
Drug: Standard nCPAP-titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nCPAP-titration
Trial: 22990619
Drug: Dextromethorphan (60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (60-120 mg/day)
Trial: 19781131
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100 microg or 4000 IU daily for 6 months)
Trial: 15906590
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release formulation of bupropion in fasting state
Trial: 15906590
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release formulation of bupropion after high fat meal
Trial: 11872895
Drug: Abciximab bolus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab bolus of 0.25 mg/kg body weight
Trial: 11872895
Drug: Standard antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antithrombotic medication (aspirin, clopidogrel, and heparin) without abciximab
Trial: 26314508
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive remediation therapy (CRT), 40 sessions
Trial: 26314508
Drug: Musical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Musical and Dancing Therapy (MDT), therapeutic contact-matched
Trial: 26314508
Drug: Musical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Musical and Dancing Therapy (MDT)
Trial: 11293557
Drug: Encapsulated 50-mg
RxNorm normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated 50-mg sumatriptan tablets
Trial: 11293557
Drug: Conventional 50-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 50-mg sumatriptan tablets
Trial: 8071850
Drug: Butorphanol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (0, 0.5, 1.0 or 2.0 mg/70 kg)
Trial: 8071850
Drug: Both butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both butorphanol and morphine
Trial: 28479216
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance therapy and Holistic Health Recovery Program for Malaysia (HHRP-M)
Trial: 28479216
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance therapy alone
Trial: 22119148
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS)
Trial: 17663102
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Duxil (control group)
Trial: 16135001
Drug: Specific oral
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific oral tolerance induction (SOTI) treatment with a maximum dose of 250 ml cow's milk or 4.5 g lyophilized hen's egg protein; daily maintenance dose of 100 ml cow's milk or 2.5 g hen's egg protein
Trial: 16135001
Drug: SOTI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOTI treatment
Trial: 2222246
Drug: GM-1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-1 treatment (100 mg by daily intramuscular injection for 12 weeks)
Trial: 22759327
Drug: Lafutidine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine at 10 mg t.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (LFT-AM)
Trial: 22759327
Drug: Rabeprazole at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole at 10 mg b.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (RPZ-AM)
Trial: 19339001
Drug: Mixed (M)
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed (M) group: rFSH and cetrorelix mixed immediately before administration
Trial: 19339001
Drug: Separate (S)
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate (S) group: rFSH and cetrorelix administered separately
Trial: 18844696
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg CP‐481715 TID
Trial: 18844696
Drug: 3000 mg
RxNorm normalized name: talc 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg CP‐481715 QD
Trial: 11923586
Drug: Metadoxine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metadoxine (900 mg intravenous)
Trial: 10373342
Drug: biosynthetic GH
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biosynthetic GH 2 IU/m2 s.c. daily (n=13)
Trial: 18410864
Drug: lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lornoxicam 8 mg (twice daily)
Trial: 18410864
Drug: diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg (twice daily)
Trial: 18410864
Drug: ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoprofen 100 mg (twice daily)
Trial: 18410864
Drug: dipyrone 1
RxNorm normalized name: dipyrone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dipyrone 1 g (three times daily)
Trial: 18410864
Drug: placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (twice daily)
Trial: 10450449
Drug: Mebendazole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (single 500 mg dose)
Trial: 10450449
Drug: Pyrantel (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrantel (single dose 12.5 mg/kg bodyweight)
Trial: 2467982
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg twice a day for 4 days
Trial: 28315319
Drug: Subcutaneous IFN‐α2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IFN‐α2a
Trial: 23266342
Drug: Intramuscular MVA85A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular MVA85A
Trial: 23266342
Drug: Intradermal MVA85A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal MVA85A
Trial: 21923715
Drug: Mesalazine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine granules (3 g/day, 3 g once daily or 1 g three times daily)
Trial: 21923715
Drug: Mesalazine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine granules (3 g/day)
Trial: 21923715
Drug: Mesalazine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine granules (once daily)
Trial: 21923715
Drug: Mesalazine tablets
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine tablets (3 g/day, 1 g three times daily)
Trial: 20027354
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens extract (reference preparation)
Trial: 17099030
Drug: Inhaled tobramycin
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin solution with oral ciprofloxacin
Trial: 17099030
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with oral ciprofloxacin
Trial: 3227053
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg (single dose)
Trial: 3227053
Drug: Rolipram 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolipram 0.75 mg (multiple dosing every 8 hours for 5 days)
Trial: 3227053
Drug: Rolipram 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolipram 1.5 mg (multiple dosing every 8 hours for 5 days)
Trial: 3227053
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (single dose)
Trial: 21401351
Drug: Articaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine (40 mL of articaine HCI 20 mg/mL with 2 mL isotonic sodium chloride solution)
Trial: 21401351
Drug: Articaine-fentanyl (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine-fentanyl (40 mL of articaine HCI 20 mg/mL with 2 mL (100 µg) of fentanyl)
Trial: 18368615
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg nocte for 2 days, 30 mg nocte for 12 days)
Trial: 16988084
Drug: Tailored weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored weight management intervention (6 monthly outpatient visits, 15 minutes each)
Trial: 10749622
Drug: Sequential GM‐CSF/bFGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential GM‐CSF/bFGF therapy
Trial: 10749622
Drug: Any cytokine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any cytokine treatment
Trial: 9361572
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous heparin for 10 days
Trial: 9361572
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous heparin for 5 days
Trial: 9361572
Drug: Pooled analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled analysis of continuous intravenous heparin
Trial: 4037710
Drug: Primperan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primperan (30 mg per day for 15 days)
Trial: 29189318
Drug: NANCAL-guided remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NANCAL-guided remifentanil administration
Trial: 29189318
Drug: Fixed remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed remifentanil concentration at 4 ng/ml
Trial: 26449721
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg amphetamine
Trial: 26449721
Drug: d-amphetamine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (various doses) in mice
Trial: 18203890
Drug: EGG group
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGG group (intake of 3 eggs per day, 640 mg/d additional dietary cholesterol)
Trial: 16434933
Drug: At least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least one neuroleptic treatment change (44.9% in public, 39.2% in private)
Trial: 12588387
Drug: Calcitriol 3
RxNorm normalized name: CALCITRIOL 3MCG/GM OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 3 microg g(-1) ointment
Trial: 12588387
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 microg g(-1) ointment
Trial: 10735152
Drug: Novel iso-osmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel iso-osmotic laxative
Trial: 8671231
Drug: Simplified ultralong
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simplified ultralong protocol (ULP) of gonadotrophin-releasing hormone agonist (GnRHa) with a single injection of 3.75 mg Decapeptyl followed by daily s.c. administration of 0.1 mg Decapeptyl for at least 2 weeks prior to ovarian stimulation.
Trial: 8671231
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol (LP) of gonadotrophin-releasing hormone agonist (GnRHa) with daily s.c. administration of 0.1 mg Decapeptyl initiated from the mid-luteal phase of the preceding cycle.
Trial: 6431075
Drug: Metered 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered 0.4 mg nitroglycerin spray
Trial: 6431075
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsule containing 0.8 mg nitroglycerin solution
Trial: 6431075
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin tablet
Trial: 31706331
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 (1 × 10^8 CFU, 5 drops once daily)
Trial: 15669595
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) at 0.025 IU/kg/day for 1 week, increasing to 0.05 IU/kg/day for 8 weeks
Trial: 15669595
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) with normal CRP levels
Trial: 10516940
Drug: Psiquial (fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psiquial (fluoxetine formulation)
Trial: 10516940
Drug: Prozac (fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prozac (fluoxetine formulation)
Trial: 7864430
Drug: Preoperative enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative enalaprilat (1.25 mg intravenously [i.v.] 20 min prior to induction)
Trial: 7864430
Drug: Intraoperative enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative enalaprilat (0.625 mg i.v. at the onset of tourniquet‐associated hypertension)
Trial: 27002298
Drug: Trabodenoson 500
RxNorm normalized name: Trabodenoson
DrugBank: Trabodenoson (DB13122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabodenoson 500 mcg
Trial: 17241298
Drug: PAC7 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC7 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg twice daily for 7 days)
Trial: 11986086
Drug: Cidofovir 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cidofovir 1% four times daily
Trial: 11986086
Drug: Cidofovir 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cidofovir 1% ten times daily
Trial: 11986086
Drug: Cidofovir 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cidofovir 1% four times daily and Cyclosporin A 1% four times daily
Trial: 11986086
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride four times daily
Trial: 7625773
Drug: Glycerol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol administration (20 g) alone
Trial: 7625773
Drug: Glycerol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol administration (20 g) with a mixed meal
Trial: 7625773
Drug: Glycerol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol administration (20 g)
Trial: 30947531
Drug: sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sustained-release bupropion (switch)
Trial: 30947531
Drug: sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sustained-release bupropion (combination)
Trial: 30947531
Drug: aripiprazole (augmentation)
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: aripiprazole (augmentation)
Trial: 28114909
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity treatment (HIT) composed of low glycemic index diet + exercise + vitamin D (60ng/mL serum concentration)
Trial: 28114909
Drug: Lower intensity
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower intensity treatment (LITE) with general advice to follow a healthy diet and exercise pattern + vitamin D to avoid insufficiency
Trial: 25451240
Drug: GABA-ergic neurotransmission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA-ergic neurotransmission via alprazolam (GABAA receptor agonist)
Trial: 20413036
Drug: hANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hANP infusion (0.02 microg/kg/min)
Trial: 17953462
Drug: OGT oral
RxNorm normalized name: OGT-2378
DrugBank: Sinbaglustat (DB17619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGT oral spray taken five times daily
Trial: 15590244
Drug: Multisensory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory therapy (n = 36 sessions for 12 weeks)
Trial: 15590244
Drug: Activity therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity therapy (n = 36 sessions for 12 weeks)
Trial: 12395981
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet containing rifampicin, isoniazid, pyrazinamide, and ethambutol
Trial: 12395981
Drug: Separate formulations
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate formulations of rifampicin, isoniazid, and pyrazinamide
Trial: 10395837
Drug: Zanamivir 2x
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir 2x daily for 5 days
Trial: 10395837
Drug: Zanamivir 4x
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir 4x daily for 5 days
Trial: 2115407
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous recombinant tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 1 hour)
Trial: 2115407
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous rt-PA (0.75 mg/kg over 1 hour; total dose, 100 mg over 6 hours)
Trial: 2115407
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (low-dose rt-PA, high-dose rt-PA, placebo)
Trial: 6111212
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 or 200 mg)
Trial: 20852079
Drug: Dietary florfenicol
RxNorm normalized name: Florfenicol
DrugBank: Florfenicol (DB11413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary florfenicol (0.02 g/kg; 16 wk)
Trial: 20852079
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of florfenicol (0.02 g/kg; 8 wk) and DVAQUA (0.5 g/kg; 8 wk)
Trial: 20852079
Drug: Dietary DVAQUA
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary DVAQUA (0.5 g/kg; 16 wk)
Trial: 16381264
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.04 microg/kg/min